A statement released earlier today by Joh. Berenberg Gossler & Co. KG about Fresenius (ETR:FRE) bumps the target price to 77.25EUR
- Updated: September 23, 2016
Joh. Berenberg Gossler & Co. KG bumped up the target of Fresenius (ETR:FRE) to 77.25EUR stating a potential upside of 0.06%.
On 09/23/2016, Joh. Berenberg Gossler & Co. KG released a statement for Fresenius (ETR:FRE) bumped up the target price from 0.00EUR to 77.25EUR that suggested an upside of 0.06%.
Boasting a price of 72.84EUR, Fresenius (ETR:FRE) traded 0.00% even on the day. With the last stock price close up 0.00% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Fresenius has recorded a 50-day average of 0.00EUR and a two hundred day average of 0.00EUR. Volume of trade held steady, with 0 shares of FRE changing hands on par with the typical 0
With a total market value of 0 EUR, Fresenius has with a one year low of 0.00EUR and a one year high of 0.00EUR .
More About Fresenius (ETR:FRE)
Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company's operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.